[F:1][C:2]1[CH:3]=[CH:4][C:5]([CH2:8][O:9][C:10]2[CH:15]=[CH:14][N:13]([CH2:16][CH2:17][C:18]3[CH:34]=[CH:33][C:21]4[CH2:22][CH2:23][N:24](C(=O)C(F)(F)F)[CH2:25][CH2:26][C:20]=4[CH:19]=3)[C:12](=[O:35])[CH:11]=2)=[N:6][CH:7]=1.[OH-].[Na+]>CO>[F:1][C:2]1[CH:3]=[CH:4][C:5]([CH2:8][O:9][C:10]2[CH:15]=[CH:14][N:13]([CH2:16][CH2:17][C:18]3[CH:34]=[CH:33][C:21]4[CH2:22][CH2:23][NH:24][CH2:25][CH2:26][C:20]=4[CH:19]=3)[C:12](=[O:35])[CH:11]=2)=[N:6][CH:7]=1To 350 mg (0.72 mmol) 4-(5-fluoro-pyridin-2-ylmethoxy)-1-{2-[3-(2,2,2-trifluoro-acetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-ethyl}-1H-pyridin-2-one (preparation 23.10a) in 10 mL MeOH is added 1.1 mL (1.10 mmol) 1 M aqueous NaOH-solution. The reaction mixture is stirred overnight at RT. After filtration is the residue purified via reverse HPLC chromatography (Waters Xbridge; water (0.3% NH4OH)/acetonitrile (0.3% NH4OH) 95:5 to 5:95).